enVVeno Medical Corp (NVNO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, enVVeno Medical Corp (NVNO) has a cash flow conversion efficiency ratio of -0.149x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.39 Million) by net assets ($29.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
enVVeno Medical Corp - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how enVVeno Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read enVVeno Medical Corp balance sheet liabilities for a breakdown of total debt and financial obligations.
enVVeno Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of enVVeno Medical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Princess Private Equity Holding Ltd
LSE:PEYS
|
-0.002x |
|
Scandinavian Brake Systems A/S
CO:SBS
|
-0.012x |
|
Titan Pharmaceuticals Inc
NASDAQ:TTNP
|
-0.244x |
|
Alefarm Brewing AS
CO:ALEFRM
|
0.019x |
|
Papyrus Australia Ltd
AU:PPY
|
15.274x |
|
Henderson Smaller Cos Inv Tst
LSE:HSL
|
0.009x |
|
Weststar Industrial Ltd
AU:WSI
|
-0.175x |
|
Ecclesiastical Insurance Office plc
LSE:ELLA
|
0.006x |
Annual Cash Flow Conversion Efficiency for enVVeno Medical Corp (2014–2024)
The table below shows the annual cash flow conversion efficiency of enVVeno Medical Corp from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see enVVeno Medical Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $42.16 Million | $-16.84 Million | -0.399x | +2.15% |
| 2023-12-31 | $46.20 Million | $-18.86 Million | -0.408x | -1.21% |
| 2022-12-31 | $38.73 Million | $-15.62 Million | -0.403x | -85.22% |
| 2021-12-31 | $54.40 Million | $-11.85 Million | -0.218x | +79.87% |
| 2020-12-31 | $7.10 Million | $-7.68 Million | -1.082x | +81.84% |
| 2019-12-31 | $989.94K | $-5.90 Million | -5.956x | -90.84% |
| 2018-12-31 | $2.04 Million | $-6.36 Million | -3.121x | -542.63% |
| 2017-12-31 | $-5.96 Million | $-4.20 Million | 0.705x | -93.51% |
| 2016-12-31 | $-283.72K | $-3.08 Million | 10.872x | +858.52% |
| 2015-12-31 | $-1.78 Million | $-2.02 Million | 1.134x | +1874180.75% |
| 2014-12-31 | $-2.01 Million | $121.74 | 0.000x | -- |
About enVVeno Medical Corp
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in … Read more